Reliable Active Pharmaceutical Ingredient Manufacturer Supporting Global Healthcare

Dronedarone Hydrochloride (CAS 141625-93-6) is the hydrochloride salt form of dronedarone, a non-iodinated benzofuran derivative developed as a Class III antiarrhythmic agent for the treatment of atrial fibrillation. Structurally related to amiodarone, Dronedarone Hydrochloride lacks the iodine moieties that are associated with amiodarone-induced thyroid and pulmonary toxicity.

Ficonalkib (CAS 2233574-95-1) is a potent, selective, third-generation inhibitor of anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase implicated in various malignancies, particularly non-small cell lung cancer (NSCLC). The molecular structure of Ficonalkib (SY-3505) features a pyrrolo[2,3-d]pyrimidine core with a dimethylaminopiperidinyl substituent and a propan-2-ylsulfonylphenyl group.

Voxilaprevir (CAS 1535212-07-7) is a macrocyclic, reversible inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Developed by Gilead Sciences, Voxilaprevir is a fluorinated macrocyclic compound featuring a complex pentacyclic scaffold with a molecular formula of C₄₀H₅₂F₄N₆O₉S. The structure of Voxilaprevir incorporates a difluoromethyl cyclopropyl sulfonylcarbamoyl moiety and a tert-butyl group, which together contribute to its high-affinity binding to the NS3/4A protease active site.

Bictegravir (CAS 1611493-60-7) is a second-generation HIV-1 integrase strand transfer inhibitor (INSTI) developed by Gilead Sciences. Chemically, it is a monocarboxylic acid amide derivative featuring a complex polycyclic core that incorporates a pyrimidine ring, a quinoline ring, and a tetrahydrofuran ring. The molecular structure of Bictegravir is characterized by a rigid, tricyclic scaffold that extends residence time on the integrase-DNA complex, a property that underpins its exceptional potency against HIV-1 strains resistant to earlier integrase inhibitors such as raltegravir, elvitegravir, and dolutegravir.

Rilzabrutinib (PRN1008) is a reversible covalent, selective, and orally active inhibitor of Bruton‘s tyrosine kinase (BTK). Structurally, Rilzabrutinib features a pyrazolo[3,4‑d]pyrimidine core with a 2‑fluoro‑4‑phenoxyphenyl substituent, a piperidine ring bearing an α,β‑unsaturated nitrile warhead, and a piperazinyl‑oxetanyl side chain.

Ibrutinib (PCI‑32765) is a first‑in‑class, orally bioavailable, irreversible small‑molecule inhibitor of Bruton‘s tyrosine kinase (BTK). Structurally, Ibrutinib features a pyrazolo[3,4‑d]pyrimidine core with a 4‑phenoxyphenyl substituent at the 3‑position, an aminopyrimidine moiety, and a piperidine ring bearing an acrylamide Michael acceptor. This molecular architecture enables Ibrutinib to form a covalent bond with Cys481 in the ATP‑binding pocket of BTK through the acrylamide warhead, resulting in irreversible enzyme inhibition.